Wegovy also received approval as a tablet – Novo Nordisk may enter a new era

Wegovy has so far been available primarily in injectable form and has been distributed mainly with insurance financing. With the tablet form, Novo Nordisk is targeting new consumer segments, especially those who have previously been averse to the needle solution and cash buyers. The company reached an agreement with the US government in November: the price of the initial monthly dose cannot exceed $149 for either those with public insurance or self-financing patients.

The move is of strategic importance, as Novo Nordisk has recently seemed to lag behind its main rival, Eli Lilly, in the injectable market, whose Zepbound (internationally known as Mounjaro) product has gained strong positions. With the tablet Wegovy, the Danish company can regain the initiative, while Lilly is also preparing to launch its own tablet consumer product in 2026.

Novo Nordisk will start distributing the tablet Wegovy in the United States in January through multiple channels – retail pharmacies, online sales platforms and telemedicine partners. The product will be available in multiple doses, but exact pricing for the higher-strength versions is not yet known.

According to the company, the new intake form can not only facilitate the entry of new patients, but also support the maintenance of long-term drug use, which is a key issue in the business and health success of weight loss therapies.